Mesoglycan

Mesoglycan

Supplement Forms / Alternate Names

Aortic GAGs; Aortic Glycosaminoglycans

Introduction

Mesoglycan is a compound found in the intestines and blood vessels. It is taken from pigs or cows and made into a supplement. It has been used to increase blood flow. Mesoglycan can be applied to the skin, taken as a pill or injected into the muscle or bloodstream by a healthcare provider.

Dosages

100 milligrams once daily

What Research Shows

May Be Effective

Not Enough Data to Assess

Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.

Safety Notes

It may be safe to take mesoglycan by mouth for a short time. Not enough studies have been done to say whether it is safe to take for a long period or by women who are pregnant or breastfeeding. The FDA has also issued a warning against using supplements that contain animal products.D1

Interactions

Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse.

References

A. Diabetic Retinopathy

A1. Pacella E, Pacella F, et al. A pilot clinical study on the effectiveness of mesoglycan against diabetic retinopathy. Clin Ter. 2012;163(1):19-22.

B. Edema

B1. Viliani T, Scarselli M, et al. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. Eur J Phys Rehabil Med. 2009 Mar;45(1):21-29.

C. Intermittent Claudication

C1. Laurora G, Ambrosoli L, et al. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994 Jun;36(2):83-86.

C2. Nenci GG, Gresele P, et al. Treatment of intermittent claudication with mesoglycan—a placebo-controlled, double-blind study. Thromb Haemost. 2001 Nov;86(5):1181-1187.

D. Safety

D1. Important alert 17-04. Federal Drug Administration website. Available at: https://www.accessdata.fda.gov/cms_ia/importalert_53.html. Accessed May 29, 2019.

E. Venous Ulcers

E1. Arosio E, Ferrari G, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg. 2001 Oct;22(4):365-372.

Last reviewed March 2020 by EBSCO NAT Review Board Eric Hurwitz, DC
Last Updated: 6/29/2020

EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

To send comments or feedback to our Editorial Team regarding the content please email us at healthlibrarysupport@ebsco.com. Our Health Library Support team will respond to your email request within 2 business days.

Home |Terms and Conditions |Concerned About Privacy? |Accessibility |Careers |For Employers and Medical Plan Providers

You may also be looking for: CVS/pharmacy | MinuteClinic | Specialty Pharmacy | SilverScript | Accordant